Optimal Management of Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma

Treatment Algorithm Based on H. pylori Status

The European Society for Medical Oncology recommends antibiotic therapy for Helicobacter pylori eradication as the optimal first-line management of gastric MALT lymphoma, which can induce lymphoma regression and long-term clinical disease control in most patients 1, 2
For localized H. pylori-positive gastric MALT lymphoma, the American Society of Clinical Oncology suggests eradication of H. pylori with antibiotics as the sole initial therapy, with a standard regimen including proton-pump inhibitor plus clarithromycin-based triple therapy with either amoxicillin or metronidazole for 10-14 days [Level II, A] [1, 3]
The National Comprehensive Cancer Network recommends confirmation of H. pylori eradication by urea breath test or stool antigen test at least 6 weeks after therapy and 2 weeks after PPI withdrawal 3
In cases of initial eradication failure, the European Society for Medical Oncology suggests second-line therapy with alternative triple- or quadruple-therapy regimens 1
For patients who achieve clinical and endoscopic remission with H. pylori eradication, the American Society of Clinical Oncology recommends waiting at least 12 months before starting another treatment, even if persistent lymphoma is present at histological level 1, 2

The European Society for Medical Oncology recommends endoscopic follow-up with multiple biopsies 2-3 months after treatment to document H. pylori eradication, and subsequently, endoscopy with biopsies should be performed at least twice per year for 2 years to monitor histological regression 2, 6
For symptomatic patients with systemic disease (stage IV), the National Comprehensive Cancer Network suggests rituximab plus chemotherapy as an appropriate treatment option [Level III, A] [4, 5]
The American Society of Clinical Oncology recommends chemotherapy options, including oral alkylating agents or purine nucleoside analogues, for refractory or advanced disease 5
The European Society for Medical Oncology suggests that rituximab has shown activity in phase II studies, and its combination with chlorambucil has proven efficacy in a randomized study [Level II, A] [5]
Patients with t(11;18) translocation are less likely to respond to antibiotics alone and will most probably be unresponsive to alkylating agents as sole treatment, according to the European Society for Medical Oncology 1, 5